27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Puma Biotechnology Inc (NASDAQ:PBYI), a company focused on developing cancer drugs, is seeing its stock hurtle to its lowest level in about 2 1/2 years following the release of its third-quarter results, which incidentally came in ahead of expectations.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Puma Biotech's Q3 total net revenue of $62.6 million exceeded the $57.9-million consensus estimate.
The company's first and only commercial product Nerlynx — used to treat early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy — raked in sales of $52.6 million, trailing expectations of $58.1 million.
The product was approved in July 2017, with shipments to wholesalers beginning at the end of July 2017.
The net loss per share narrowed from $2.07 to 37 cents. The consensus had called for a loss of 97 cents per share.
As of September, the company had cash and cash equivalents of $68.3 million and marketable securities of $59.7 million.
Reacting to the results, Barclays lowered the price target on Puma Biotech shares from $72 to $29.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
JPMorgan downgraded the stock from Overweight to Underweight.
What's Next
Notwithstanding the domestic softness in Nerlynx, Puma is making inroads into the international market with its breast cancer drug. It received European Commission approval for the drug in the third quarter.
The company expects Nerlynx to be commercially launched in Germany in the first half of 2019 and subsequently in additional European countries throughout the second half of 2018.
Canada accepted the New Drug Submission in Q3, while in China, Puma Biotech's licensing partner CANbridge Pharma was informed of China's National Medical Products Administration accepting the NDA.
Puma Biotech shares were plummeting 51.4 percent to $18.76 at the time of publication Friday.
Related Links:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.